Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence

Abstract

Stem/progenitor cells have been widely evaluated as a promising therapeutic option for heart failure (HF). Numerous clinical trials with stem/progenitor cell-based therapy (SCT) for HF have demonstrated encouraging results, but not without limitations or discrepancies. Recent technological advancements in multiomics, bioinformatics, precision medicine, artificial intelligence (AI), and machine learning (ML) provide new approaches and insights for stem cell research and therapeutic development. Integration of these new technologies into stem/progenitor cell therapy for HF may help address: 1) the technical challenges to obtain reliable and high-quality therapeutic precursor cells, 2) the discrepancies between preclinical and clinical studies, and 3) the personalized selection of optimal therapeutic cell types/populations for individual patients in the context of precision medicine. This review summarizes the current status of SCT for HF in clinics and provides new perspectives on the development of computation-aided SCT in the era of precision medicine and AI/ML.

Evaluating the predictive value of angiogenesis-related genes for prognosis and immunotherapy response in prostate adenocarcinoma using machine learning and experimental approaches

“…Gene enrichment analysis indicated that MAP7D3 is not only linked to angiogenesis but also to stem cell pathways. Stem cells are precursor cells that have the ability to self-renew and differentiate into functionally mature, specialized cells in various human tissues Stem cells are precursor cells that have the ability to self-renew and differentiate into functionally mature special cells in various tissues of the human body ( 45 ). Importantly, evidence suggests that the interplay between tumor angiogenesis and cancer stem cells promotes tumor growth.…”

Multi-omics analysis and experimental validation of the value of monocyte-associated features in prostate cancer prognosis and immunotherapy

“…Moreover, there is evidence to suggest that circulating monocyte levels could serve as a biomarker for metastatic PRAD, indicating a notably unfavorable prognosis (12). Integrated multi-omics, machine learning, and artificial intelligence are being more frequently utilized in the field of medicine (13)(14)(15)(16)(17). It is essential to conduct further analysis on levels of tumorinfiltrating immune cells and identify genes related to immune cell infiltration using multi-omics and machine learning techniques to enhance the accuracy of diagnosis and treatment for PRAD.…”